

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA dostarlimab with carboplatin and paclitaxel for treating primary advanced or recurrent endometrial cancer

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
No equalities issues raised at scoping

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
N/A

3. Has any change to the draft scope been agreed to highlight potential equality issues?
N/A

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

Approved by Associate Director (name):Janet Robertson

Technology Appraisals: Scoping

Equality impact assessment for the proposed single technology appraisal for dostarlimab with carboplatin and paclitaxel for treating primary advanced or recurrent endometrial cancer

Issue date: May 2023

Date:16 May 2023